The lancet oncology
-
The lancet oncology · Jul 2022
Multicenter StudyCabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide). We aimed to evaluate cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties, in combination with the PD-L1 inhibitor atezolizumab in metastatic castration-resistant prostate cancer. ⋯ Exelixis.
-
The lancet oncology · Jul 2022
Multicenter StudyOutcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. ⋯ National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust.
-
The lancet oncology · Jul 2022
Randomized Controlled TrialWeekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly (ie, once every 3 weeks) carboplatin. However, this benefit was not observed in the previously reported progression-free survival results of ICON8. Here, we present the final coprimary outcomes of overall survival and updated progression-free survival analyses of ICON8. ⋯ Cancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, and Cancer Australia.
-
The lancet oncology · Jul 2022
Randomized Controlled TrialHigh incidence of severe pain is associated with low opioid availability in patients with advanced cancer: a nationwide questionnaire survey in Japan.
Opioid availability for the palliative care of patients with advanced cancer is increasing globally. However, opioid consumption in Japan is still extremely low compared with that in other countries. We investigated the current situation of pain control and opioid consumption in patients with advanced cancer in Japan. ⋯ This study was funded by the authors and by Shionogi (Osaka, Japan), Nippon Zoki Pharmaceutical (Osaka, Japan), and Heartfelt (Kumamoto, Japan).
-
The lancet oncology · Jul 2022
Observational StudyImpact of the COVID-19 pandemic on the diagnosis of cancer in Japan: an observational study of hospital-based cancer registries data.
There is an important concern that the COVID-19 pandemic has negatively affected cancer care worldwide. We used a national database to assess the effect of the COVID-19 pandemic on the diagnosis of cancer in Japan. ⋯ This study was supported by the Health, Labour and Welfare Policy Research Grants, Research for Promotion of Cancer Control Programmes (reference 21EA2003), and the Cancer Research and Development Fund of the National Cancer Centre, Japan (reference 2020-A-20).